Jeff Garro
Stock Analyst at Stephens & Co.
(1.10)
# 3,552
Out of 4,840 analysts
49
Total ratings
33.33%
Success rate
-12.54%
Average return
Main Sectors:
Stocks Rated by Jeff Garro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBRG TruBridge | Reiterates: Equal-Weight | $28 | $24.08 | +16.28% | 3 | Apr 10, 2025 | |
| VEEV Veeva Systems | Reiterates: Overweight | $280 | $238.06 | +17.62% | 2 | Mar 6, 2025 | |
| HCAT Health Catalyst | Maintains: Equal-Weight | $7 → $5 | $3.78 | +32.45% | 4 | Mar 6, 2025 | |
| CERT Certara | Reiterates: Overweight | $17 | $11.55 | +47.19% | 5 | Feb 27, 2025 | |
| EVH Evolent Health | Maintains: Equal-Weight | $16 → $12 | $7.70 | +55.84% | 5 | Jan 21, 2025 | |
| PRVA Privia Health Group | Reiterates: Overweight | $26 | $23.32 | +11.49% | 3 | Jan 7, 2025 | |
| DH Definitive Healthcare | Initiates: Equal-Weight | $5 | $3.28 | +52.44% | 1 | Dec 20, 2024 | |
| DOCS Doximity | Initiates: Equal-Weight | $55 | $52.10 | +5.57% | 1 | Dec 20, 2024 | |
| OPRX OptimizeRx | Initiates: Equal-Weight | $5.5 | $12.64 | -56.49% | 3 | Dec 20, 2024 | |
| IQV IQVIA Holdings | Initiates: Overweight | $250 | $140.54 | +77.89% | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $18.10 | -6.08% | 1 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $39 | $32.25 | +20.93% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $28 | $24.95 | +12.22% | 8 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $28 | $7.08 | +295.48% | 2 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $14.76 | +35.50% | 3 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $5 → $3.9 | $4.03 | -3.23% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $2.21 | +35.75% | 3 | May 6, 2022 |
TruBridge
Apr 10, 2025
Reiterates: Equal-Weight
Price Target: $28
Current: $24.08
Upside: +16.28%
Veeva Systems
Mar 6, 2025
Reiterates: Overweight
Price Target: $280
Current: $238.06
Upside: +17.62%
Health Catalyst
Mar 6, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $3.78
Upside: +32.45%
Certara
Feb 27, 2025
Reiterates: Overweight
Price Target: $17
Current: $11.55
Upside: +47.19%
Evolent Health
Jan 21, 2025
Maintains: Equal-Weight
Price Target: $16 → $12
Current: $7.70
Upside: +55.84%
Privia Health Group
Jan 7, 2025
Reiterates: Overweight
Price Target: $26
Current: $23.32
Upside: +11.49%
Definitive Healthcare
Dec 20, 2024
Initiates: Equal-Weight
Price Target: $5
Current: $3.28
Upside: +52.44%
Doximity
Dec 20, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $52.10
Upside: +5.57%
OptimizeRx
Dec 20, 2024
Initiates: Equal-Weight
Price Target: $5.5
Current: $12.64
Upside: -56.49%
IQVIA Holdings
Dec 20, 2024
Initiates: Overweight
Price Target: $250
Current: $140.54
Upside: +77.89%
Dec 9, 2024
Initiates: Buy
Price Target: $17
Current: $18.10
Upside: -6.08%
Nov 15, 2024
Initiates: Overweight
Price Target: $39
Current: $32.25
Upside: +20.93%
May 31, 2024
Reiterates: Overweight
Price Target: $28
Current: $24.95
Upside: +12.22%
Jul 26, 2023
Reiterates: Equal-Weight
Price Target: $28
Current: $7.08
Upside: +295.48%
Aug 5, 2022
Maintains: Overweight
Price Target: $15 → $20
Current: $14.76
Upside: +35.50%
May 11, 2022
Maintains: Underweight
Price Target: $5 → $3.9
Current: $4.03
Upside: -3.23%
May 6, 2022
Maintains: Neutral
Price Target: $4 → $3
Current: $2.21
Upside: +35.75%